莱芜黑山羊卵巢FSHr、LHr的免疫组化定位研究

为从形态学角度理解内分泌调节过程,揭示促性腺激素(GTH)对雌性哺乳动物卵巢调节作用机制,对处于非繁殖季节的莱芜黑山羊卵巢中FSHr、LHr分布进行免疫组化SABC方法定位.分别选取相邻的6张连续阳性切片,光镜观察、图像分析.结果显示:FSHr、LHr阳性细胞主要分布于卵泡颗粒细胞、膜细胞、卵母细胞、血管周围间质,尤其以在卵泡颗粒细胞、膜细胞的胞质中分布最多.原始卵泡卵母细胞中便有两种受体阳性物质分布,在各级卵泡中两种受体阳性细胞数量、染色强度随卵泡发育水平呈正向增加趋势.     

奶牛卵泡超数同步发育及其卵母细胞的发育潜能

目的建立促奶牛卵泡超数同步发育的方法,并利用体细胞核移植和分子技术评价来自这些卵泡的卵母细胞发育潜能。方法用E2-P4对淘汰的高产奶牛进行联合处理后,分别对其实施不同组合的外源促性腺激素处理[FSH12h组,FSH48h组,FSH48h-LH6h组（简称LH6h组）,FSH48h-LH26h组（简称LH26h组）]以促进其卵泡超数同步发育;然后从卵泡中回收COCs进行体外成熟,排放第一极体的卵供作优质种牛的体细胞核转移（nucleartransfer,NT）受体,以评价卵的发育潜能。结果E2-P4能成功地诱导奶牛卵巢中产生一个新的卵泡起始波,并能保证卵泡在外源促性腺激素作用下实现超数同步发育;上述四组不同组合外源促性腺激素处理的卵母细胞衍生的NT重构胚经体内培养7d后,后3组的囊胚发育率显著高于FSH12h组和对照组（P〈0.01）;将这些克隆囊胚移植同步发情的受体牛子宫后,仅LH26h组的卵所获得的克隆胚能实现全程发育（直至克隆小牛出生）。经RT-PCR分析颗粒细胞中FSHr、LHr和连接蛋白43（Connexin43,Cx43）等mRNA含量变化,以及Western印迹分析其Bcl-2和Bax蛋白表达水平的变化,证实该组卵巢提供的同步发育卵泡为早期闭锁卵泡。结论E2-P4-FSH48h-LH26h组合处理可人为调控牛卵泡的同步发育;处于早期闭锁状态卵泡的卵母细胞具备较高的发育潜能。     

甾体激素合成快速调节蛋白mRNA在卵泡发育和闭锁过程的表达

以孕马血清促性腺激素（ＰＭＳＧ）激发的ＳＤ大鼠卵巢为模型,用３′－末端原位标记和形态健康卵泡和闭锁卵泡,用原侠杂交方法研究了在卵泡发育和闭锁过程中甾体激素合成快速调节蛋白（ＳｔＡＲ）ｍＲＮＡ的表达规律。发现ＳｔＡＲｍＲＮＡ在膜－间质细胞和黄体化颗粒细胞中表达,未黄体化颗粒细胞和卵母细胞均无表达。ＰＭＳＧ注射后１２小时卵巢内已有ＳｔＡＲｍＲＮＡ的表达,２４小时表达量升高,７２小时表达量达高峰。ＰＭＳ     

小鼠卵巢冷冻移植后卵泡发育和卵母细胞成熟的研究

本研究探讨了冷冻保存的1日龄小鼠卵巢异体异位移植后,其原始卵泡重新启动生长发育的能力。一日龄B6C2F．小鼠卵巢分离冷冻后置液氮中保存,保存1周。6个月后解冻,并将卵巢移植到8-12周龄B6C2F．受体鼠。肾脏包膜下,移植至少14d。每侧肾囊移植2枚卵巢的40只受体鼠中卵巢的回收率为45．00％（72／160）,而每侧。肾囊移植l枚卵巢的20只受体鼠的回收率为82．50％（33／40）。移植卵巢上卵泡的发育基本与体外自然生长鼠的卵巢卵泡发育情况一致。对卵巢移植19d的受体鼠用孕马血清促性腺激素（pregnant mare serum gonadotrophin,PMSG）处理后,从移植卵巢上发育成熟卵泡中获得的卵母细胞在MEM0c培养基中培养16-17h,有40．90％的卵母细胞发生生发泡破裂（germinal vesicle breakdown,GVBD）,其中89．02％的卵母细胞发育到第二次减数分裂中期（metaphaseⅡ,MⅡ）。将剩余的卵母细胞继续培养到20～21h,又有50．83％的卵母细胞发生生发泡破裂,但其中只有21．40％的卵母细胞能够发育到MII期。以上结果说明,小鼠早期卵巢经过冷冻．解冻并异体异位移植后,其原始卵泡能够重新启动生长发育,发育后的卵泡卵母细胞能够在体外培养成熟。这些结果意味着原始卵泡或卵巢冷冻一移植技术有可能充分利用雌性生殖细胞用于濒危动物保种、建立动物基因库和人类辅助生殖等。     

哺乳动物腔前卵泡体外培养研究进展

哺乳动物卵巢中含有数以万计的腔前卵泡（preantral follicles）,仅不足1％能够发育至预排卵卵泡。建立哺乳动物腔前卵泡有效分离及体外培养技术体系,能够大量利用腔前卵泡,增加体外成熟卵母细胞数量,对哺乳动物胚胎体外生产、克隆及转基因动物生产等胚胎工程技术的研究与应用,以及在体外条件下揭示哺乳动物卵泡发育机理,都具有重要的理论意义和实用价值。鉴于卵巢质地与卵泡划、发生周期的固有差异,不同物种腔前卵泡分离方法与培养方式亦有所不同。同时,培养基类型、卵泡问相互作用、促性腺激素与细胞因子等因素均会对卵泡的体外发育产生影响。系统阐述了腔前卵泡的分离方法、培养方式以及相关因素对卵泡发育的影响,期望为从事相关研究的学者提供参考。     

新生小鼠卵巢移植雄鼠肾囊下卵泡的生长发育

将1日龄小鼠卵巢移植入成年雄鼠肾囊下,分别于移植后18d、36d回收移植卵巢进行形态学、组织学观察,以评价卵巢移植体在成年雄性受体小鼠体内生长及卵泡发育潜能。结果表明:移植体生长增大,有各级生长卵泡发育;18日龄移植体平均直径为1881.1μm±204.7μm,与1日龄卵巢相比差异极显著(P<0.01),卵泡发育到有腔卵泡阶段;36日龄移植体平均直径达2575.3μm±466.4μm,显著大于18日龄移植体(P<0.01),有成熟卵泡出现,未观察到黄体;从移植体分离到GV期卵母细胞和卵丘卵母细胞复合体。研究表明1日龄小鼠卵巢移植体在雄性受体生理环境中具有正常生长发育和形成成熟卵泡的潜能。     

哺乳动物卵巢卵泡发育调控机制研究进展

卵巢作为雌性哺乳动物的性腺,是由卵母细胞和不同类型的体细胞组成的异质性器官。卵巢在功能上,一方面担负了与雌性个体健康有关的内分泌调节功能,另一方面则承载了产生成熟卵母细胞并繁衍子代的重要任务。而承担上述功能的单位为卵泡,即卵母细胞和卵泡体细胞共同构成的复合体。对于具有较长生殖寿命的哺乳动物而言,卵泡在卵巢内的发育是一个内部协同与外部调控的精密有序过程。其中后期促性腺激素依赖的有腔卵泡发育直接调控生殖周期的产生,而近期越来越多的证据表明早期卵泡的有序发育与雌性生殖寿命维持密切关联。因此,卵泡在体正常发育与雌性个体的健康息息相关;而深入探索卵泡发育调控机制,可直接指导我们认识包括人类在内的雌性哺乳动物生殖寿命的维持机制,并在未来对其进行可能的调控。近年来,伴随着新技术和新方法的产生,特别是基因修饰动物的开发以及新型显微技术的出现,对卵泡发育特别是早期卵泡发育的调控机制研究有了长足的进步。本综述围绕着卵泡在体发育中的关键生理事件,将近年来对卵泡的生理发育调节机制研究进行梳理,并重点聚焦于早期卵泡发育的体内相关调控机制研究进展。     

原始卵泡形成与早期卵泡发育的遗传调控

原始卵泡形成与早期发育调控对卵母细胞发育来说非常重要,通过对原始卵泡的体外培养,可以了解原始卵泡发育的调节机制.原始卵泡向初级卵泡的转变不依赖于促性腺激素,而主要受卵巢旁分泌因子的调控,包括Kit/KL、GDF9等促进因子和AMH等抑制因子的调控.目前,原始卵泡发育的分子调控机理研究多以小鼠为模型,而对大型哺乳动物和人的研究甚少.概述了哺乳动物原始卵泡形成与发育启动调控机制的既有研究成果,详细阐述了原始卵泡发育过程中关键分子的调控作用,并介绍了小鼠及其他哺乳动物卵泡体外培养的研究进展.     

扬子鳄卵巢性类固醇激素受体的免疫细胞化学研究

为探讨扬子鳄卵巢内不同性类固醇激素受体在卵泡发育中的调控作用,研究采用组织学和免疫细胞化学方法,运用激光共聚焦显微镜,对扬子鳄不同发育时期卵泡中的雌激素受体、雄激素受体和孕激素受体进行了检测。结果发现,3种类固醇激素受体在卵巢各期滤泡细胞中均有表达,在4月Ⅱ-Ⅳ期卵泡的滤泡细胞中阳性反应最强;9月卵巢的滤泡细胞中阳性反应最弱;ER和AR不仅在各期滤泡细胞中存在阳性位点,在6月卵泡的卵母细胞胞质中也有表达。结果说明,在扬子鳄卵母细胞生长发育和成熟过程中,3种激素受体通过与其对应的激素结合对滤泡细胞的发育、卵黄的合成与积累以及排卵起着重要的调控作用。       

PMSG或FSH同期发情处理对小鼠卵巢、输卵管和子宫中孕激素受体分布的影响

目的探讨孕马血清促性腺激素（pregnant mare serum gonadotropin,PMSG）和促卵泡激素（folliclestimulating hormone,FSH）同期发情处理的小鼠卵巢、输卵管和子宫中孕激素受体（progesterone receptor,PR）分布的差异。方法 10只8周龄KM系雌鼠,随机分为PMSG和FSH两个组,第一次处理后48 h取其卵巢、输卵管、子宫进行固定,免疫组织化学法观察各组织中PR的分布。结果两组小鼠卵巢、输卵管和子宫内膜中均有PR表达;其中PMSG组初级卵泡、次级卵泡和输卵管的阳性率均显著高于FSH处理组（P〈0.05）;PMSG组各级卵泡的平均吸光度值均显著高于FSH处理组（P〈0.05）;PMSG处理组子宫内膜上皮与腺上皮中的阳性率显著高于FSH组（P〈0.05）,而基质和子宫内膜上皮中的平均吸光度值显著低于FSH组（P〈0.05）。结论 PMSG和FSH同期发情处理不同程度影响小鼠卵巢、输卵管和子宫中PR的表达分布;其中PMSG处理组小鼠卵巢、输卵管和子宫上皮中PR表达普遍显著高于FSH处理组。     

Effects of luteinizing hormone releasing hormone on gonadotrophins in the hamster

The changes in serum gonadotrophins in male hamsters following one injection of 15 μg luteinizing hormone releasing hormone (LHRH) (Group A) were compared with those following the last injection of LHRH in animals receiving an injection approximately every 12 hr for 4 days (Group B) or 12 days (Group C). Peak follicle stimulating hormone (FSH) levels (ng/ml) were 1776±218 (Group A), 2904±346 (Group B), and 4336±449 (Group C). Peak luteinizing hormone (LH) values (ng/ml) were 1352±80 (Group A), 410±12 (Group B), and 498±53 (Group C). Serum FSH:LH ratios, calculated from the concentrations measured 16 hr after the last LHRH injections, were higher in Groups B and C than in Group A. Similar injections of LHRH (100 ng or 15 μg/injection) for 6 days elevated the serum FSH:LH ratio in intact males. Five such LHRH injections (100 ng/injection) blunted the rise in serum LH in orchidectomized hamsters. Direct effects of LHRH on gonadotrophin secretory dynamics or altered brain-pituitary-testicular interactions may alter the ratio of FSH to LH in the hamster.     

Melatonin and gonadotropin secretion after acute exercise in physically active males

Serum concentrations of luteinizing hormone (LH), follicle stimulating hormone, testosterone (T) and melatonin were measured in seven physically active male volunteers after exercise on a treadmill using the Bruce protocol. Measurements were made on blood samples obtained before exercise, within 30 s after exercise, at 15 min after exercise, and subsequently at 30-min intervals after exercise for a total duration of 180 min. Serum LH concentration fell from a peak post-exercise level of 15.7 (4.7) IU·l^–1 [mean (SD)] to a nadir of 10.3 (2.4) IU·l^–1 (P<0.004). Nadir values in individual volunteers were seen between 60 and 150 min after exercise. This fall in serum LH was paralleled by a similar fall in the concentration of serum T. Serum melaonin concentrations did not change significantly after exercise. It is concluded that melatonin, despite is reported anti-gonadotropic properties, does not play a role in the depression of serum LH after acute strenuous exercise in physically active males     

双峰驼血浆促卵泡素的放射免疫分析法

用单峰驼促卵泡素标准品（ＣａｍＦＳＨ）,ｈＦＳＨ抗血清和＾１２５Ｉ－ｈＦＳＨ建立了测定双峰驼血浆ＦＳＨ的放射免疫分析方法,并通过一系列实验证明,该方法可以用于测定双峰驼血浆ＦＳＨ,是研究双峰驼生殖内分泌学的可靠手段之一。     

Cyclic changes of plasma spermine concentrations in women

Based on previous studies which suggest that blood polyamines fluctuate during the menstrual cycle, the present study was set to determine whether plasma concentrations of the polyamine spermine show menstrual cycle-associated changes and if so, how these changes relate to phasic variations in other female hormones. Blood samples were collected from a group of 9 healthy women of various ages at 5 defined periods during their menstrual cycle including 1 woman on oral contraceptives. Spermine concentrations were determined in plasma acid extracts by reversed-phase high performance liquid chromatography method. Plasma estradiol, LH and FSH were measured by microparticle enzyme immunoassay using an automatic analyzer. Spermine concentrations, 104.4 +/- 12.2 nmol/ml at 1-3 day of the cycle, were increased transiently with a peak (263.8 +/- 22.1 nmol/ml) at 8-10 day and declined to 85.4 +/- 29.8 nmol/ml by 21-23 day of the cycle. The peak spermine concentrations coincided with the first increase in plasma estrogen levels. The individual variations in the temporal profile of spermine concentrations were of similar magnitude as individual differences in other female hormones. We conclude that: a) Plasma spermine concentrations undergo distinct cyclic alterations during the menstrual cycle with peak concentrations coinciding with the first estradiol increase, and b) Peak plasma spermine concentrations occur during the follicular phase, just prior to ovulation, during the period of rapid endometrial growth.     

Oestradiol and the preovulatory surges of luteinising hormone and follicle stimulating hormone in ewes during the breeding season and transition into anoestrus

This study was designed to see if giving exogenous oestradiol, during the follicular phase of the oestrous cycle of intact ewes, during the breeding season or transition into anoestrus, would alter the occurrence, timing or magnitude of the preovulatory surge of secretion of luteinising hormone (LH) or follicle stimulating hormone (FSH). During the breeding season and the time of transition, separate groups of ewes were infused (intravenously) with either saline (30 ml h⁻¹; n = 6) or oestradiol in saline (n = 6) for 30 h. Infusion started 12 h after removal of progestin-containing intravaginal sponges that had been in place for 12 days. The initial dose of oestradiol was 0.02 μg h⁻¹; this was doubled every 4 h for 20 h, followed by every 5 h up to 30 h, to reach a maximum of 1.5 μg h⁻¹. Following progestin removal during the breeding season, peak serum concentrations of oestradiol in control ewes were 10.31 ± 1.04 pg ml⁻¹, at 49.60 ± 3.40 h after progestin removal. There was no obvious peak during transition, but at a time after progestin removal equivalent to the time of the oestradiol peak in ewes at mid breeding season, oestradiol concentrations were 6.70 ± 1.14 pg ml⁻¹ in ewes in transition (P < 0.05). In oestradiol treated ewes, peak serum oestradiol concentrations (24.8 ± 2.1 pg ml⁻¹) and time to peak (41.00 ± 0.05 h) did not differ between seasons (P > 0.05). During the breeding season, all six control ewes and four of six ewes given oestradiol showed oestrus with LH and FSH surges. The two ewes not showing oestrus did not respond to oestrus synchronisation and had persistently high serum concentrations of progesterone. During transition, three of six control ewes showed oestrus but only two had LH and FSH surges; all oestradiol treated ewes showed oestrus and gonadotrophin surges (P < 0.05). The timing and magnitude of LH and FSH surges did not vary with treatment or season. In blood samples collected every 12 min for 6 h, from 12 h after the start of oestradiol infusion, mean serum concentrations of LH and LH pulse frequency were lower in control ewes during transition than during mid breeding season (P < 0.05). Oestradiol treatment resulted in lower mean serum concentrations of LH in season and lower LH pulse frequency in transition (P < 0.05). We concluded that enhancing the height of the preovulatory peak in serum concentrations of oestradiol during the breeding season did not alter the timing or the magnitude of the preovulatory surge of LH and FSH secretion and that at transition into anoestrus, oestradiol can induce oestrus and the surge release of LH and FSH as effectively as during the breeding season.     

Plasma follicle stimulating hormone and luteinizing hormone patterns during the estrous cycle of ewes

Fifteen Suffolk ewes were used in three experiments to compare plasma follicle stimulating hormone (FSH) and luteinizing hormone (LH) patterns during the estrous cycle and to determine whether FSH levels undergo changes in pulse frequency. Luteinizing hormone changed inversely with progesterone levels whereas FSH and progesterone concentrations revealed no obvious relationship. Unlike LH, FSH levels did not pulsate during the follicular phase. Higher FSH levels were detected on days 1, 6 and 12 and lower levels on days 0, 4 and 16. Coincident preovulatory LH and FSH surges were observed and this was the only time FSH and LH levels appeared to be jointly controlled.     

Regulation of FSH receptor promoter activation in the osteoclast

We have shown recently that FSH stimulates osteoclast formation and function by a direct action on a G(i)-coupled FSH receptor (FSHR). Here, we report properties of the mouse FSH receptor promoter in the context of its activation in RAW-C3 osteoclast precursor macrophages. Basal promoter activity was low, but was significantly stimulated by receptor activator for NF-kappaB-ligand (RANK-L), a critical osteoclastogenic and pro-resorptive cytokine. In contrast, FSH dampened FSHR promoter activation, while estrogen had no effect. We surmise that the FSHR expression is regulated distinctly in the osteoclast, and differently from other cells, such as the ovarian follicular and Leydig cells.     

二甲双胍对多囊卵巢综合征肥胖型患者LH和FSH的影响

目的：探讨二甲双胍对多囊卵巢综合征肥胖型患者血清中胰岛素、LH和FSH水平的影响。方法：将84例PCOS肥胖型患者随机分成44例对照组（克罗米芬）和40例观察组（二甲双胍）,采用放射免疫法测定黄体生成素（LH）和卵泡刺激素（FSH）的水平,分别于服药前（0分钟）和服后60、120分钟经前臂静脉采血,测血糖浓度及血清胰岛素水平。结果：对照组患者治疗前0min、60min及120min的血糖OGTT分别为（4．57±0．25）mmol／L、（8．38±7．05）mmol/L（7.21±0．12）mmol／L。治疗后0min、60min及120min的血糖OGTT无明显变化。观察组患者治疗前0min、60min及120min的血糖OGTT分别为（4．11±0．31）mmol／L、（8．23±6．57）mmol／L及（7．25±0．13）mmol／L,治疗后0min、60min及120min的血糖0GTT明显降低。对照组患者治疗前血清中胰岛素为（47．32±9．52）U／ml,治疗后为（42．25±7．65）U／ml,治疗前后无明显差异。观察组患者治疗前血清中胰岛素为（46．41±6．11）U／ml,治疗后血清胰岛素水平明显降低。对照组患者治疗后血清中LH为（17．22±2．14）mU／ml,FSH为（1．24±0．33）mU／ml,而与对照组相比,观察组患者血清中的LH明显降低,而FSH水平升高。结论：二甲双胍导致多囊卵巢综合征患者血清中胰岛素水平降低,从而减轻了胰岛素对LH的刺激作用,使LH水平下降,FSH升高,进而改善机体的激素紊乱,最终达到治疗PCOS的目的。     

二甲双胍对多囊卵巢综合征肥胖型患者LH 和FSH 的影响

目的:探讨二甲双胍对多囊卵巢综合征肥胖型患者血清中胰岛素、LH和FSH水平的影响。方法:将84例PCOS肥胖型患者随机分成44例对照组(克罗米芬)和40例观察组(二甲双胍),采用放射免疫法测定黄体生成素(LH)和卵泡刺激素(FSH)的水平,分别于服药前(0分钟)和服后60、120分钟经前臂静脉采血,测血糖浓度及血清胰岛素水平。结果:对照组患者治疗前0min、60min及120min的血糖OGTT分别为(4.57±0.25)mmol/L、(8.38±7.05)mmol/L及(7.21±0.12)mmol/L,治疗后0min、60min及120min的血糖OGTT无明显变化。观察组患者治疗前0min、60min及120min的血糖OGTT分别为(4.11±0.31)mmol/L、(8.23±6.57)mmol/L及(7.25±0.13)mmol/L,治疗后0min、60min及120min的血糖OGTT明显降低。对照组患者治疗前血清中胰岛素为(47.32±9.52)U/m l,治疗后为(42.25±7.65)U/ml,治疗前后无明显差异。观察组患者治疗前血清中胰岛素为(46.41±6.11)U/ml,治疗后血清胰岛素水平明显降低。对照组患者治疗后血清中LH为(17.22±2.14)mU/ml,FSH为(1.24±0.33)mU/m l,而与对照组相比,观察组患者血清中的LH明显降低,而FSH水平升高。结论:二甲双胍导致多囊卵巢综合征患者血清中胰岛素水平降低,从而减轻了胰岛素对LH的刺激作用,使LH水平下降,FSH升高,进而改善机体的激素紊乱,最终达到治疗PCOS的目的。     

Glycan mapping of recombinant human follicle stimulating hormone by mass spectrometry

In humans, regulation of reproductive functions are carried out mainly by glycoprotein hormones namely follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH) and chorionic gonadotropin (CG). Since glycans play an important role in binding of gonadotropins with their respective receptors, it is important to identify associated glycans and their pharmacological properties not only for the disease manipulation but also for making more efficacious and safer recombinant versions. With the advancement of mass spectrometry, it is possible to identify minute quantity of associated glycans. Here, we studied the N-glycans of the FSH based on mass spectrometry and report one more complex glycan species in addition to twenty four previously reported glycans. The new glycan was a tetra antennary species that may have important role in binding of FSH with receptor with higher biological activity as well as lower clearance rate and higher half-life.